Prerpints.org logo
Preprint
Review

Probiotics in the Treatment of Gastrointestinal Disorders and What We Know About Their Effect on Microbiota

Altmetrics

Downloads

120

Views

40

Comments

0

This version is not peer-reviewed

Gut Microbiota in Human Health

Submitted:

17 August 2023

Posted:

21 August 2023

You are already at the latest version

Alerts
Abstract
Modulating the gut microbiota with probiotics has been identified as a promising therapeutic method for the management of gastrointestinal illnesses. The effectiveness of probiotics in the treatment of gastrointestinal disorders can only be determined by delving into their underlying mechanisms of action. Through an analysis of the underlying processes, this study hopes to provide light on the potential benefits of probiotics for treating a variety of gastrointestinal conditions. The study covers a wide variety of gastrointestinal conditions, such as IBS, IBD, and antibiotic-associated diarrhea. Modifying the gut microbiota composition, strengthening the gut barrier function, modulating the immune system, and producing beneficial metabolites are among mechanisms of action that have been investigated. The strain- and dose-specific variables essential to getting the best treatment results are also highlighted. This review, which synthesizes the current information, gives a thorough overview of the effectiveness of probiotics in treating a variety of gastrointestinal illnesses and illuminates potential avenues for further study and therapeutic use.
Keywords: 
Subject: Biology and Life Sciences  -   Immunology and Microbiology

1. Introduction

For a long time, it has been difficult and complex for healthcare providers to treat digestive system diseases. In recent years, it has become clearer than ever before how the microbiota of the gut interacts with the immune system and general gastrointestinal health [1]. The potential of probiotics as a therapeutic intervention for gut illnesses has attracted substantial interest as research continues to disclose the vital function of the gut microbiota in maintaining a healthy gut. Improving gut health and controlling different gut problems with the help of probiotics, which are defined as living microorganisms that offer health advantages when taken in suitable proportions, has emerged as a potential path. Some kinds of bacteria and yeasts have been discovered to positively affect digestion, immunity, and inflammation by altering the makeup and activity of the gut microbiota. Probiotics' ability to shed light on microbiota modification has spawned novel approaches to tackling gastrointestinal illnesses as a whole. Probiotics provide a novel strategy for reestablishing gastrointestinal homeostasis by modulating immune responses, improving gut barrier function, and reestablishing microbial equilibrium. In this overview, we'll look at the many ways in which probiotics can help with the treatment of gastrointestinal problems by altering the composition of the gut microbiota. This study aims to give a complete knowledge of the potential of probiotics as a therapeutic strategy by analyzing the mechanisms of action, effectiveness in various gastrointestinal illnesses, and factors for strain selection [2]. This review will also examine the latest findings on the gut-brain axis and the effect of probiotics on mental health, illuminating the interconnected nature of the digestive system and the brain in the treatment of gastrointestinal disorders. The risk-benefit profile of these therapies will also be explored, as this knowledge is essential for clinical practice and includes the use of probiotics. This review intends to shed light on the function of probiotics in the therapy of gastrointestinal illnesses by critically evaluating the existing data and exploring potential future approaches, with the goal of offering insights for academics and healthcare practitioners. In conclusion, probiotics provide a novel approach to the treatment of gastrointestinal illnesses by influencing the composition of the gut microbiota and the way it interacts with the host. The entire potential of probiotics in the therapy of gastrointestinal disorders and the improvement of patient outcomes depends on a thorough understanding of their mechanisms, effectiveness, and safety [3].

2. Understanding How Probiotics Work to Repair the Microbiota in Your Gut:

The human gut microbiota, an intricate ecology of bacteria found in the digestive tract, is essential to one's health and well-being. Diseases of the digestive tract and the body as a whole have been linked to shifts in the delicate balance of the gut microbiota [4]. Recent years have seen a surge in interest in the medicinal potential of probiotics for improving health by reestablishing a healthy balance of gut bacteria. Modulating the gut microbiota using probiotics, which are defined as living bacteria that give health advantages when supplied in suitable proportions, has shown promise. Beneficial microorganisms, such as some types of bacteria and yeasts, can influence the gut ecology by interacting with the native microbiota [5]. To fully use the therapeutic potential of probiotics, it is essential to understand the processes by which they achieve this equilibrium in the gut flora. Probiotics have been shown to have an effect on the gut microbiota through a number of different methods. Competitive exclusion, immunological regulation, antimicrobial substance generation, and metabolic activity are all examples of such pathways. Probiotics' capacity to compete with and prevent the growth of pathogenic or dangerous microbes in the gut is referred to as competitive exclusion [6]. Probiotics can restore microbial balance by preventing the overgrowth of pathogenic bacteria by colonizing empty niches and using scarce resources. Additionally, probiotics modulate intestinal immune responses by interacting with the host immune system. They can boost production of anti-inflammatory cytokines, control immune cell activity, and foster healthy immune system development. These immune-suppressing actions help keep the gastrointestinal tract in balance and stop inflammation before it gets out of hand. Organic acids, hydrogen peroxide, and bacteriocins are only some of the antimicrobial compounds that probiotics have been shown to generate. These compounds, which have antibacterial capabilities and can limit the growth of infections, offer a new strategy for reestablishing a healthy microbiota in the digestive tract. Probiotics' metabolic activity is a key mechanism in the regulation of gut microbiota. Fermentation of dietary fibers and other substrates by probiotic microorganisms results in the production of SCFAs such butyrate, propionate, and acetate. Colonocytes rely on SCFAs for energy, and their use has been linked to a number of health advantages, such as improved gut barrier function and reduced immune response sensitivity [7].
In conclusion, probiotics' ability to restore the normal composition of the gut microbiota is the result of a complex process involving several modes of action. Probiotics improve the composition of the gut microbiota by a number of mechanisms, including competitive exclusion, immunological regulation, antimicrobial chemical synthesis, and metabolic activity. To improve the therapeutic effectiveness of probiotic therapies for gastrointestinal illnesses, it is crucial to understand these pathways. To better treat gut-related illnesses and develop individualized probiotic therapy, further study of the complex relationships between probiotics, the gut microbiota, and host health is required [8].

3. Probiotics' Role in Treating Ailments of the Digestive System:

Many different diseases and ailments can impact the digestive system, and all of them can cause unpleasant symptoms and lower a person's quality of life [9]. Probiotics have gained attention as a possible treatment for gastrointestinal problems in recent years. Live bacteria known as probiotics have been found to be effective in treating a wide range of gastrointestinal disorders when taken in therapeutic doses. Probiotics come in many forms, but they all work by colonizing the gut and interacting with the microbiota already there. The capacity of these bacteria to modify gut health and treat symptoms of various gut illnesses has been the subject of substantial research. This has led to the consideration of probiotics as a viable supplemental or alternative to standard medical treatment for various ailments. The purpose of this extensive analysis is to assess the effectiveness of probiotics in treating particular gastrointestinal conditions. To offer a thorough overview of the state of the art in this sector, we will be delving deeply into the data from clinical trials and systematic reviews. This review will focus on gastrointestinal conditions such as diarrhea brought on by antibiotic use, infectious gastroenteritis, and irritable bowel syndrome. Several different pathophysiological pathways contribute to these disorders. These include shifts in gut microbial composition, intestinal inflammation, and gastrointestinal motility problems [10].
Possible ways by which probiotics may ameliorate certain gastrointestinal problems will also be examined. The gut microbiota can be rebalanced, immune responses can be modulated, the gut barrier can be strengthened, and antimicrobial compounds can be produced [11]. In order to assess the efficiency of various probiotic strains, formulations, and doses in treating particular gastrointestinal illnesses, this review will thoroughly examine the existing literature, including randomized controlled trials and meta-analyses. Both objective and subjective measurements, such as changes in symptoms, disease activity ratings, and biomarker levels, will be considered as part of the outcomes of interest. Potential restrictions and difficulties in probiotics study will also be discussed [12]. These may include the requirement for standardized guidelines and recommendations for the use of probiotics in certain gastrointestinal illnesses, as well as variances in study methods and the variability of probiotic formulations. The ultimate goal of this in-depth analysis is to synthesize the available research concerning the effectiveness of probiotics in treating particular gastrointestinal illnesses. Understanding the possible advantages, limits, and future directions of using probiotics as a therapeutic intervention in the management of various illnesses will be aided by the results of this study [13].

4. The Role of Probiotics in the Treatment of Irritable Bowel Syndrome:

Crohn's disease and ulcerative colitis are two forms of inflammatory bowel disease (IBD), a chronic gastrointestinal inflammatory condition with a complicated and multiple origin. IBD continues to be difficult to treat despite advancements in medical care, necessitating typically a mix of pharmaceutical therapies and lifestyle changes. There has been a significant uptick in research on the use of probiotics as an auxiliary treatment for inflammatory bowel disease (IBD) [14]. There is growing evidence that probiotics, which are described as "live microorganisms that confer health benefits when administered in adequate amounts," might alter the composition of microbes in the digestive tract and influence the immune system [15]. Changes in gut microbiota composition have been linked to inflammatory bowel disease (IBD) etiology and illness progression. Thus, probiotic therapies aimed at the gut microbiota have emerged as a potentially useful strategy for dealing with IBD. The purpose of this article is to look at the current research and where probiotics could go in the future as an adjuvant therapy for inflammatory bowel disease. To offer a thorough overview of the state of the art in this subject, we will be examining the available literature, which includes clinical trials and systematic reviews [16].
Potential methods by which probiotics may ameliorate inflammatory bowel disease will be investigated. Mechanisms include normalizing the composition of gut microbes, altering immunological responses, strengthening the intestinal barrier, and reducing inflammation. To better understand the function of probiotics in IBD and to choose the most effective strains, formulations, and dosing for therapeutic treatments, a deeper understanding of these pathways is required [17]. This study will systematically examine the existing literature to assess the performance of various probiotic strains and formulations for the treatment of IBD. Disease activity ratings, endoscopic findings, inflammatory laboratory markers, quality of life evaluations, and adverse events will all be of relevance as outcomes to track. The possibility for adverse effects and interactions with concomitant pharmaceutical therapy of probiotics in IBD patients will also be evaluated in this research. Future probiotic research for IBD will also be discussed in this article. Particularly intriguing are efforts to tailor probiotic treatments to each person's unique microbiota, the use of combination probiotic medicines, and the creation of tailored delivery methods. In order to create strong evidence and direct clinical practice, the review will also discuss the significance of conducting well-designed clinical trials using standardized methodology [18].
The overarching goal of this study is to supply an evidence-based examination of probiotics as supplementary treatment for IBD. Its goal is to help readers better grasp the possible advantages and limitations associated with probiotic therapy in IBD management by critically analyzing the existing evidence and exploring potential future paths. This information will ultimately aid physicians and researchers in developing the most effective probiotic treatment plans for people with IBD [19].

5. Understanding the Role of Probiotics in Maintaining Mental and Digestive Health:

The gut-brain axis is the two-way line of communication between the digestive system and the brain. This complex link permits ongoing bidirectional communication between the digestive tract and the brain via neuronal, hormonal, and immune pathways. Recent years have seen a rise in interest in the possible function of probiotics in altering the gut-brain axis as new information highlights the major influence of the gut microbiota on mental health and gastrointestinal illnesses [20]. The billions of bacteria that make up the gut microbiota play a significant role in homeostasis and general well-being. Anxiety, depression, and stress disorders, as well as gastrointestinal conditions like irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), have all been linked to dysbiosis, or a disruption in the composition of the gut microbiota.
Probiotics have gained popularity due to their ability to alter both gastrointestinal and central nervous system functions by reestablishing a healthy balance in the gut flora. Many probiotic bacteria have been explored for their potential to ameliorate symptoms of mental health illnesses and gastrointestinal diseases through modulating the gut-brain axis.
The purpose of this extensive analysis is to examine the impact of the gut-brain axis on mental health and gastrointestinal illnesses, with an emphasis on the possible involvement of probiotics in this nuanced relationship. The impact of probiotics on mental health outcomes such anxiety, depression, stress resilience, and cognitive function will be reviewed, both in preclinical and clinical settings. In addition, the effects of probiotics on gastrointestinal conditions such irritable bowel syndrome and inflammatory bowel disease will be assessed by looking at symptoms, gut microbiota composition, and inflammatory markers. We will talk about the potential processes through which probiotics affect the gut-brain axis [21]. Producing neuroactive chemicals, controlling the immune system, modifying the gut epithelial barrier, and interacting with the enteric nervous system are all examples of such methods. The potential therapeutic effects of probiotics in mental health and gastrointestinal problems can only be understood by gaining insight into these pathways [22]. Strain-specific effects, variability of study designs, and the need for further mechanistic studies will all be discussed as well as other difficulties and limits of probiotic research in this area that will be addressed in this overview. Individual differences in gut microbiota composition, genetics, and lifestyle variables will be discussed, as will the significance of tailored methods in probiotic therapy. This study intends to shed light on the potential of probiotics in altering mental health and gastrointestinal diseases via the gut-brain axis by analyzing the current data and gaps in understanding. These results have the potential to inform the design of innovative treatment methods and interventions aimed at the gut microbiota for the prevention and management of mental health diseases and gastrointestinal illnesses [23].
In conclusion, research into the link between mental health and gastrointestinal problems should benefit from focusing on the gut-brain axis. Probiotics have recently gained attention as a promising method for influencing this axis and boosting emotional and physical wellness. The purpose of this article is to offer a thorough study of the current literature on the topic of probiotics and the gut-brain axis by covering such topics as mechanisms, clinical results, and potential future research areas. In the end, a deeper comprehension of this intricate relationship can lead to novel strategies for enhancing mental health and mitigating gastrointestinal illnesses via probiotic therapies [24].

6. Factors to Consider and Difficulties to Overcome When Choosing Probiotic Strains for the Treatment of Specific Digestive Disorders:

Significant interest has been brought to the possible therapeutic effects of probiotics on gastrointestinal illnesses. Probiotics are defined as living microorganisms that give health benefits when supplied in suitable doses. Successful outcomes in targeted gastrointestinal disorder care rely heavily on the selection of the proper probiotic strains. However, it can be difficult to go through the wide variety of strains and zero in on the best options for treating particular gastrointestinal diseases. The purpose of this essay is to shed light on the factors to consider and difficulties to overcome when choosing probiotic strains for the therapy of specific gastrointestinal disorders [25].
1. The Pathophysiology of Digestive Disorders Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), and Antibiotic-Induced Diarrhea each have unique causes and symptoms. Selecting probiotic strains that have shown effectiveness in regulating particular pathways related to each gastrointestinal condition is crucial. Some strains may exhibit antibacterial activity helpful for antibiotic-associated diarrhea, while others may have anti-inflammatory qualities helpful for inflammatory bowel disease.
2. Strain-Specific Effects Many different probiotic strains exist, each with its own unique set of properties and capabilities. The capacity to attach to the gut epithelium, produce antibiotic compounds, or alter immunological responses are just a few examples of how each strain could be different. Therefore, it is important to choose strains that have been well examined and demonstrated to have beneficial benefits for the intended gastrointestinal condition.
3. Probiotic strain selection should be backed by solid clinical data and extensive research. The results of clinical trials investigating the usefulness of various strains in the treatment of digestive diseases are instructive. It is essential to evaluate the quality and design of clinical research in order to ascertain the validity of the data. The selection process can be aided by meta-analyses and systematic reviews, which give a thorough overview of the relevant research.
4. To be effective, probiotic strains must be able to make it through the stomach acid, intestinal mucus, and other nasties on their way to the proper location. Probiotic viability and efficacy may be altered by stomach acid, bile salts, and digestive enzymes. Consequently, it is crucial to ensure their therapeutic potential by choosing strains that are known to resist these circumstances and have showed a high survival rate.
5. When choosing probiotic strains, it is crucial to prioritize safety, especially for people with weakened immune systems or preexisting illnesses. It is essential to evaluate the possibility for side effects, the lack of antibiotic resistance genes, and the track record of safety of the selected strains. If you want further help making sure your chosen probiotic strains are safe, you may look to the guidelines and recommendations put forward by regulatory agencies.
6. Individualized treatment plans: gastrointestinal problems and the effects of probiotics on different people might vary widely. Probiotic therapies may be more successful if tailored to each person based on their unique gut microbiota makeup, genetics, lifestyle, and nutrition. Next-generation sequencing and metabolomics are two examples of cutting-edge technologies that hold promise for individualizing probiotic recommendations. Lack of defined criteria, study design variability, and the need for further research are all obstacles to choosing the best probiotic strains for the focused care of gastrointestinal disorders. In addition, it might be difficult to assess and choose the best commercial product because different goods may include different strains or mixes [26].
In conclusion, managing a gastrointestinal condition specifically requires careful consideration when choosing a probiotic strain. Gut disorder-specific processes, strain-specific effects, clinical data, compatibility with the gut environment, safety, and individualized treatments should all play a role in the decision-making process. Maximizing the therapeutic potential of probiotics in the therapy of gastrointestinal illnesses can improve patient outcomes and quality of life if these concerns and obstacles are addressed and overcome [27].

6. The Risk-Benefit Analysis of Probiotics for the Treatment of Digestive Disorders:

The potential therapeutic effects of probiotics, which are living microorganisms that offer health advantages when taken in suitable proportions, on gastrointestinal illnesses have received a great deal of interest. Risk-benefit analyses of medical interventions, including probiotics for the treatment of gastrointestinal problems, are essential. The purpose of this essay is to shed light on the need to weigh the risks and benefits of using probiotics for the treatment of gastrointestinal disorders [26,27,28,29,30,31,32,33,34].
1. Due to their lengthy history of usage in fermented foods and nutritional supplements, probiotics have earned the reputation of being completely safe for human ingestion. The most popular probiotics come from the Bacillus and Bifidobacterium families. These microorganisms have a low risk to humans and are generally well tolerated by everyone from infants to the elderly. It's important to remember, though, that different strains may have different safety profiles.
2. Although side effects from taking probiotics are uncommon, they can occur, and they tend to be minor and short-lived. Bloating, gas, stomach pain, and diarrhea are all possible side effects. These reactions normally subside on their own, without the need for treatment. Differentiating between negative reactions to probiotics and those due to the underlying gastrointestinal illness or an individual's unique response is essential.
3. People with weakened immune systems, such as those undergoing chemotherapy, receiving an organ transplant, or living with HIV/AIDS, should proceed with caution when taking probiotics. In immunocompromised people, infections linked to certain probiotic strains have been reported, however this is extremely unusual. Therefore, the risk-benefit ratio needs to be carefully monitored and assessed on an individual basis.
4. There is a small risk of invasive infections with some probiotic strains, most notably those of the genera Lactobacillus and Bifidobacterium, however this is more common in those with preexisting illnesses or a compromised immune system. Although the danger of invasive infection from probiotics is small, it is crucial to highlight that the advantages of their use frequently outweigh the risks.
5. The safety characteristics of different probiotic strains might vary widely. Antibiotic resistance genes, putative virulence factors, and genomic stability are just a few strain-specific traits that must be taken into account. Risks can be reduced by selecting strains that have been used safely in the past and that have been the subject of extensive scientific study and regulatory approval.
6. Each potential patient receiving probiotics for the treatment of a digestive illness should have the risk-benefit ratio calculated specifically for them. Probiotics may help with symptoms, restore gut microbial balance, and potentially prevent disease, but there are hazards and personal considerations to think about before taking them. Assessing the risk-benefit ratio of probiotics requires consulting with healthcare specialists, taking into account the individual's medical history, and monitoring the reaction to probiotics.

7. Conclusion:

In the treatment of gastrointestinal problems, probiotics show great promise. Although they have a high margin of safety, the risk-benefit analysis for treating gastrointestinal disorders must be performed. Probiotics seldom cause major side effects, and any that do occur are often moderate and short-lived. Evaluation of immunocompromised patients is complicated by the need to take into account strain-specific safety characteristics. Healthcare providers and patients alike can make more educated judgments about the use of probiotics in the treatment of gastrointestinal illnesses if they weigh the benefits against the hazards.

References

  1. Afzal M, Mazhar SF, Sana S, Naeem M, Rasool MH, Saqalein M; et al. Neurological and cognitive significance of probiotics: A holy grail deciding individual personality. Future Microbiol. 2020, 15, 1059–1074. [Google Scholar] [CrossRef] [PubMed]
  2. Markowiak P, Slizewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients 2017, 9. [CrossRef]
  3. Kazemian N, Mahmoudi M, Halperin F, Wu JC, Pakpour S. Gut microbiota and cardiovascular disease: Opportunities and challenges. Microbiome. 2020, 8, 36. [Google Scholar] [CrossRef]
  4. Hills RD Jr, Pontefract BA, Mishcon HR, Black CA, Sutton SC, Theberge CR. Gut microbiome: Profound implications for diet and disease. Nutrients. 2019, 11. [Google Scholar] [CrossRef]
  5. Panebianco C, Andriulli A, Pazienza V. Pharmacomicrobiomics: Exploiting the drug-microbiota interactions in anticancer therapies. Microbiome. 2018, 6, 92. [Google Scholar] [CrossRef]
  6. Khan AA, Shrivastava A, Khurshid M. Normal to cancer microbiome transformation and its implication in cancer diagnosis. Biochem. Biophys. Res. Commun. 2012, 1826, 331–337. [Google Scholar] [CrossRef]
  7. Khan AA, Nema V, Khan Z. Current status of probiotics for prevention and management of gastrointestinal cancers. Expert Opin. Biol. Ther. 2020, 20, 1–9. [Google Scholar] [CrossRef]
  8. Khan AA, Khurshid M, Khan S, Alshamsan A. Gut microbiota and probiotics: Current status and their role in cancer therapeutics. Drug Dev. Res. 2013, 74, 365–375. [Google Scholar] [CrossRef]
  9. Sedighi M, Zahedi Bialvaei A, Hamblin MR, Ohadi E, Asadi A, Halajzadeh M; et al. Therapeutic bacteria to combat cancer: Current advances, challenges, and opportunities. Cancer Med. 2019, 8, 3167–3181. [Google Scholar] [CrossRef]
  10. Zur, HH. The search for infectious causes of human cancers: Where and why. Virology. 2009, 392, 1–10. [Google Scholar] [CrossRef]
  11. Ishaq S, Nunn L. Helicobacter pylori and gastric cancer: A state of the art review. Gastroenterol Hepatol Bed Bench. 2015, 8 Suppl. 1, S6–S14.
  12. Khan AA, Abuderman AA, Ashraf MT, Khan Z. Protein-protein interactions of HPV-Chlamydia trachomatis-human and their potential in cervical cancer. Future Microbiol. 2020, 15, 509–520. [Google Scholar] [CrossRef]
  13. Khan AA, Khan Z, Malik A, Kalam MA, Cash P, Ashraf MT; et al. Colorectal cancer-inflammatory bowel disease nexus and felony of Escherichia coli. Life Sci. 2017, 180, 60–67. [Google Scholar] [CrossRef] [PubMed]
  14. Khan AA, Khan Z, Malik A, Shrivastava A, Jain SK, Alshamsan A. Computational prediction of Escherichia coli proteins targeting the host cell nucleus, with special reference to their role in colon cancer etiology. Cancer Lett. 2015, 364, 25–32. [Google Scholar] [CrossRef] [PubMed]
  15. Khan, AA. In silico prediction of Escherichia coli proteins targeting the host cell nucleus, with special reference to their role in colon cancer etiology. J. Comput. Biol. 2014, 21, 466–475. [Google Scholar] [CrossRef] [PubMed]
  16. Khan AA, Cash PE. E. coli and colon cancer: Is mutY a culprit? Cancer Lett. 2013, 341, 127–131. [Google Scholar] [CrossRef]
  17. Tewari M, Mishra RR, Shukla HS. Salmonella typhi and gallbladder cancer: Report from an endemic region. HBPD INT. 2010, 9, 524–530. [Google Scholar]
  18. Sheflin AM, Whitney AK, Weir TL. Cancer-promoting effects of microbial dysbiosis. Curr. Oncol. Rep. 2014, 16, 406. [Google Scholar] [CrossRef]
  19. Jenkins SV, Robeson II MS, Griffin RJ, Quick CM, Siegel ER, Cannon MJ; et al. Gastrointestinal tract dysbiosis enhances distal tumor progression through suppression of leukocyte trafficking. Cancer Res. 2019, 79, 5999–6009. [Google Scholar] [CrossRef]
  20. Gao Z, Guo B, Gao R, Zhu Q, Qin H. Microbiota disbiosis is associated with colorectal cancer. Front Microbiol. 2015, 6, 20. [Google Scholar] [CrossRef]
  21. Xuan C, Shamonki JM, Chung A, Dinome ML, Chung M, Sieling PA; et al. Microbial dysbiosis is associated with human breast cancer. PLoS ONE. 2014, 9, e83744. [Google Scholar] [CrossRef]
  22. Malla MA, Dubey A, Kumar A, Patil A, Ahmad S, Kothari R, Yadav S. Optimization and elucidation of organophosphorus and pyrethroid degradation pathways by a novel bacterial consortium C3 using RSM and GC-MS-based metabolomics. J Taiwan Inst Chem Eng. 2021, 144, 104744. [Google Scholar]
  23. Munot N, Kandekar U, Rikame C, Patil A, Sengupta P, Urooj S, Bilal A. Improved Mucoadhesion, Permeation and In Vitro Anticancer Potential of Synthesized Thiolated Acacia and Karaya Gum Combination: A Systematic Study. Molecules. 2022, 27, 6829. [Google Scholar] [CrossRef] [PubMed]
  24. Munot N, Kandekar U, Giram PS, Khot K, Patil A, Cavalu S. A Comparative Study of Quercetin-Loaded Nanocochleates and Liposomes: Formulation, Characterization, Assessment of Degradation and In Vitro Anticancer Potential. Pharmaceutics. 2022, 14, 1601. [Google Scholar]
  25. Manikyam HK, Tripathi P, Patil SB, Lamichhane J, Chaitanya M; et al. Extraction, purification, and quantification of hesperidin from the immature Citrus grandis/maxima fruit Nepal cultivar. Asian J Nat Prod Biochem. 2020, 20. [Google Scholar]
  26. Patil A, Munot N, Patwekar M, Patwekar F, Ahmad I, Alraey Y, Alghamdi S; et al. Encapsulation of lactic acid bacteria by lyophilization with its effects on viability and adhesion properties. Evid. Based Complementary Altern. Med. 2022, 2022. [Google Scholar]
  27. Nalawade AS, Gurav RV, Patil AR, Patwekar M, Patwekar F. A comprehensive review on morphological, genetic and phytochemical diversity, breeding and bioprospecting studies of genus Chlorophytum Ker Gawl. from India. Trends Phytochem. Res. 2022, 6, 19–45. [Google Scholar]
  28. Patil KG, Balkundhi S, Joshi H, Ghewade G. Mehsana buffalo milk as prebiotics for growth of Lactobacillus. Int J Pharm Pharm Res. 2011, 1, 114–117. [Google Scholar]
  29. Das N, Ray N, Patil AR, Saini SS, Waghmode B, Ghosh C, Patil SB; et al. Inhibitory effect of selected Indian honey on colon cancer cell growth by inducing apoptosis and targeting the β-catenin/Wnt pathway. Food & Funct. 2022, 13, 8283–8303. [Google Scholar]
  30. Patil MJ, Patil AG, Patil DA, Patil SP, Patil AR. Screening and characterization of antifungal substances from probiotics against Candida species. Int J Pharm Pharm Res. 2013, 4, 149–156. [Google Scholar]
  31. Munot NM, Shinde YD, Shah P, Patil A, Patil SB, Bhinge SD. Formulation and Evaluation of Chitosan-PLGA Biocomposite Scaffolds Incorporated with Quercetin Liposomes Made by QbD Approach for Improved Healing of Oral Lesions. AAPS PharmSciTech. 2023, 24, 147. [Google Scholar]
  32. Patil, A. Psychology in the Age of Technology Dependence and the Mobile Dilemma. Preprints.org. 2023, 2023070101. [Google Scholar] [CrossRef]
  33. Patil A, Kotekar D, Chavan G. Knowing the Mechanisms: How Probiotics Affect the Development and Progression of Cancer. Preprints.org. 2023, 20236070243. [CrossRef]
  34. Pawar V, Patil A, Tamboli F, Gaikwad D, Mali D, Shinde A. Harnessing the Power of AI in Pharmacokinetics and Pharmacodynamics: A Comprehensive Review. Int. J. Pharm. Qual. Assur. 2021, 14, 426–439. [Google Scholar]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated